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interaction inhibitor and optimized synthesis via phosphine free remote 
group directed hydroarylation 
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Phospine free hydroarylation reaction applied to norbornene derivatives is described for the first time and was exploited for the regioselective gram scale 
synthesis of AR-148 a known Rac1-Tiam1 PPI inhibitor. Umpolung conversion of nitro group to the free amine allowed the regiocontrol of the key arylation 
step via long range effect. Pharmacological evaluation of the two enantiomers showed the enantioselectivity of the inhibitor and represents the first study 
case of enantiopure inhibitor of Rac1-Tiam1 PPI 
Introduction 
The small GTPase protein Rac1 has gained attention for its role 
in different pathologies, among which cancer and 
cardiovascular disease [1]. Rac1 regulates events such as 
smooth muscle cell (SMC) migration [2] and proliferation, [3] 
and leukocyte-endothelial cell interaction [4].  Rac1 activity 
depends on the equilibrium between the inactive GDP-bound 
and the active GTP-bound forms. This cycling is regulated by the 
guanine nucleotide exchange factors (GEFs) which act as 
activators, and the GTPase activating proteins (GAPs) and GDP 
dissociation inhibitors (GDIs) which act as negative regulators. 
The T-cell lymphoma invasion and metastasis 1 (Tiam1) protein, 
a specific GEF for Rac1, is crucial for cell-cell adhesion and cell 
migration.  
Small molecules interfering with the Rac1-Tiam1 Protein-
Protein Interaction (PPI) were identified and reported by us [5-
6] and by others [7-11]. (Figure 1a) Afterwards we reported the 
identification of 2-amino-3-(phenylsulfanyl)norbornane-2-
carboxylate as a privileged scaffold for the de novo design and 
synthesis of a structurally original family of Rac1 inhibitors [12]. 
(Figure 1b) 
G-LISA assay on SMCs demonstrated that among all the 
compounds tested, 1 (named AR-148) selectively and potently 
inhibits Rac1 without interfering with RhoA. Boyden chamber 
chemotaxis assay and Cell movement video microscopy analysis 
have shown how 1 (AR-148) affects cell migration in response 
to the chemotactic agent platelet derived growth factor BB 
(PDGF-BB) [12].  
In our previous work we designed and performed a divergent 
synthetic strategy from which the entire class of aryl 2-amino-
3-(phenylsulfanyl)norbornane-2-carboxylate was obtained.  
 
Figure 1. Previous work: a) First generation of Rac-Tiam1 inhibitors; b)Target compound 
AR-148 obtained in racemic form; c) AR-148 synthesis drawbacks:  -compound 4, 
precursor of AR-148, is the minor reaction product, - 2* used as racemate of the two 
enantiomers 
The main difference between AR-148 and the others known 
Rac1-Tiam1 PPI inhibitors (Figure 1a, 1b) consists in the 
presence of a three dimensional core heavily functionalized that 
places aromatic groups involved in π-π interactions or π-cation 
interactions in very precise way. (Figure 2) 
 
Figure 2. AR-148 Molecular interaction surface of Rac1-AR-148 [12] 
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In modern drug discovery, compounds with three dimensional 
structure that escape the ‘’flatland’’ of multiple arenes, became 
more central because of  higher level of insaturation and the 
presence of multiple stereocenters. The resulting structural 
complexity seems to provide better receptor ligand interaction 
with consequent improved potency, selectivity and decreased 
off-target effect [13]. 
Focusing our attention on the efficient preparation of the most 
active compound AR-148 we identified two main drawbacks.  
Firstly, the hydroarylation reaction was performed in a classical 
way in the presence of Ph3P and excess of iodoarene (3 equiv.) 
and gave the C-6 arylated isomer, precursor of AR-148, as the 
minor isomer (3:4=70:30) [14]. (Figure 1c) Secondly, compound 
AR-148 was obtained in racemic form. Nowadays, defining the 
activity of both enantiomers is extremely important because of 
the great impact on reducing unexpected toxicity in the further 
drug development. Moreover, once defined the eutomer, its 
precise pharmacophore model could deeply improve the 
rational design of new derivatives. As a consequence, the 
preparation of the two enantiomers in pure form is crucial to 
evaluate their activity independently. In this work we report an 
efficient protecting group free, gram scale selective synthesis of 
compound AR-148, the obtainment, via chromatographic 
separation, of both enantiomers and their pharmacological 
evaluation.  
 Results and discussion 
Chemistry. 
To optimize the synthesis of AR-148 in an eco-friendly way, we 
reasoned that a phosphine-free hydroarylation protocol could 
be of outstanding interest. Many phosphine ligands are 
expensive, toxic, unrecoverable and often water- and air-
sensitive. In large-scale applications on industrial and semi-
industrial scale, the phosphines might be a serious economic 
burden. Therefore we considered performing the reaction in 
absence of phosphine [15]. To our knowledge phosphine-free 
Heck hydroarylation has never been realized on olefins and the 
only examples reported are limited to alkyne substrates [16,17]. 
So we planned to perform the hydroarylation using the same 
conditions described before, but in absence of the phosphine 
ligand (Pd(OAc)2/TEA/HCOOH in CH3CN). The progressive 
addition to racemate 2 of 3-iodoaniline (1 equiv. x 3 every 4h) 
at lower temperature (50°C instead of 82°C) gave the same 
mixture of regioisomers 3 and 4 in higher yield (80% instead of 
75%) but with the same ratio. (Scheme 1)  
 
Scheme 1. Phosphine free methodology. Reagents and conditions: (a) Pd(OAc)2 5%, TEA 
3.5 equiv., HCOOH 3.0 equiv., CH3CN, 50°C, (80%) *) used as racemate of the 2 
enantiomers 
The theoretical work done by M.B. Hall on the mechanism of 
ligand-free Heck type arylation [18-20] and the works published 
by Cacchi on phosphine-free Heck hydroarylation on alkyne, 
[16,17] shed light on the different possible scenarios regarding 
the mechanism of our reaction. Unfortunately, the presence of 
a slight excess of an organic base like TEA, the use of a 
coordinative solvent such as CH3CN, the requirement of formic 
acid and the substrate itself, containing the norbornene core 
(ligand in the Catellani reaction [21]), make very difficult to 
prove which catalytic cycle is really operating or if there are 
more than one operating at the same time. It is worthy to report 
that different solvents have been screened (DMF, DMSO, 
CH3CN, DCM, MeOH, THF, DCE, Et2O) and have always led, even 
if with variable yield, to the formation of the desired product. 
(Figure 1, SI) The good conversion obtained in DCE underlined 
how the reaction works, even in the absence of a coordinative 
solvent, in accordance with the formation of dianionic species 
isolated by Hartwig and co-workers for the ligand-free Heck 
arylation [19]. Once a fairly satisfactory result was obtained 
which demonstrated the feasibility of a phosphine free 
hydroarylation protocol, we turned our attention to the 
selectivity of the Heck hydroarylation that is in fact the 
divergent point in the synthesis of 4, precursor of the desired 
compound AR-148. In order to modulate the regioselectivity in 
favour of 4 instead of 3, several attempts were performed by 
using different reaction conditions but without satisfactory 
results [22- 24]. (Table 1, SI) 
Our previous studies [14, 25] disclosed that the regioselectivity 
is mainly driven by long range effect exerted by the nitro group 
on C-2, (Path a, Figure 3) [26, 27]. We thus decided to exploit 
the Umpolung conversion of the nitro- to the amine group 
reasoning that an opposite long range effect should induce an 
inverse charge distribution of the double bond and 
consequently an opposite regiochemistry could be obtained 
(Path b, Figure 3). 
 
 
Figure 3. Umpolung conversion of nitro- to amino group to modulate the long range 
effect on the Hydroarylation reaction 
By treating compound 2 with Zn/H3PO4 in THF from 0 °C to r.t., 
amine precursor 5 has been prepared in very good yield (97%). 
(Scheme 2)  
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After a brief optimization (Table 2 SI) to identify the adequate 
reaction conditions compound 7 and 8 have been obtained 
(yield 88%, 82% for the grams scale) by reacting 5 under the 
phosphine-free protocol, previously optimized, 
(Pd(OAc)2/TEA/HCOOH in CH3CN).  
 
 
Scheme 2. Reagents and conditions: a) Zn, H3PO4 1M, THF, 0°C-rt, 2 gram scale; b) Phosphine free methodology m-Iodoaniline 1.1 equiv., Pd(OAc)2,TEA, HCOOH, CH3CN, 45°C, 1 gram 
scale; c) 4-Iodonitrobenzene 1.1 equiv., Pd(tetrakis), K2PO4, CH3CN, 70°C, 1 gram scale; d) Zn, HCl 1M, MeOH, 0 °C, 1h, 1 gram scale; *) used as racemate of the 2 enantiomers 
§)absolute stereochemistry of compounds (-)-10, (+)-10, (-)-AR148 and (+)-AR148 has not been attributed . 
As expected thanks to an opposite long range effect, an inverse 
C5/C6 ratio was found being the regioisomer 8, precursor of AR-
148, the main product of the reaction (7 : 8 = 30 : 70). 
Coordination of palladium by the free amine in endo position of 
5 can not been excluded but is a non-productive pathway for 
the Heck Hydroarylation reaction, in fact no endo-product has 
been detected on norbornene core. [28-30] (See SI page S7 for 
NMR characterization and assignment of exo-substituted 
compounds 7 and 8) 
  The use of phosphine free protocol has been fundamental to 
obtain the desired compound as single reaction product and to 
improve the atom economy of the process. Indeed the 
undesired Buchwald-Hartwig reaction of m-iodo aniline on itself 
or on the norbornene aliphatic amine of 5 does not work in 
absence of phosphine while the Heck arylation is not affected. 
Undesired derivative of 5 is completely suppressed and the 
amount of m-iodo aniline 6 is reduced from 3.0 to 1.1 
equivalents. Polymers of m-iodo aniline were in fact always 
isolated using the previous reaction conditions. (Table 2 SI)  
Buchwald-Hartwig amination has been tested directly on the 
inseparable mixture of 7 and 8. Using Pd(tetrakis), K3PO4 and 1.4 
equiv. 4-iodonitrobenzene in MeCN, compounds 9 and 10 were 
obtained in almost quantitative yield (90%). K3PO4 is required 
instead of Cs2CO3 to avoid the arylation of the aminoester 
functionality on norbornene core. The compounds 9 and 10 
have been separated by flash chromatography and structure 
was confirmed by NMR analysis. (Structural elucidation SI). By 
performing the reduction of the nitro group of 10 with Zn/HCl 
1M in MeOH at 0 °C, compound (±)AR-148 was obtained in a 
very efficient way. The whole protocol was scaled up and 1 gram 
of compound (±)AR-148 was obtained without the use of any 
protective group, higher atom economy, higher overall yield 
and in a regioselective way avoiding the use of phosphine in the 
Heck reaction. (Scheme 2) 
Finally, we faced the problem related to the availability of the 
two enantiomers of AR-148 for the pharmacological tests. We 
focused on the enantioselective synthesis of norbornene 
scaffold 2 obtained through the Diels-Alder cycloaddition 
reaction [12]. We tried to perform the reaction by using chiral 
catalysts, but although we observed an enhanced selectivity, 
very low yields always affected our results. The synthesis of 
chiral dienophiles (-sulfanyl nitroacrylate esters of (-)menthol 
and (-)8-Ph-menthol) was very troublesome and the yields were 
not suitable as a first step of the synthesis. Therefore, we 
considered the exploitation of a removable chiral auxiliary to 
obtain the separation of the two corresponding 
diastereoisomers of AR-148. By reacting the free amine of AR-
148 with (-) menthylchloroformate the two corresponding 
monomenthylcarbamate diastereoisomers were obtained and 
easily separated by HPLC, but unfortunately the further 
hydrolysis of the chiral auxiliary always led to unreacted 
compounds or tarry materials. 
Finally, through the use of chiral HPLC we separated the two 
enantiomers of AR-148 with unsatisfactory results.  However, 
excellent results were obtained in the chiral HPLC resolution of 
racemate (±)-10 (see SI), (Scheme 2). The two enantiomers (-)-
10 and (+)-10 were obtained with high enantiomeric purity 
(purity: >99% ee: >99). 
After reduction of the single enantiomers (Zn/HCl in MeOH at 0 
°C) the corresponding amines (-)AR-148 and (+)AR-148 were 
obtained. NMR analyses were performed confirming the 
structure and the purity of the final compounds. 
Pharmacology 
  
  
The effect of AR-148 and its enantiomers on Rac1 activation was 
investigated in human cultured smooth muscle cells (SMCs). 
Interestingly, the (-)AR-148 enantiomer reduced the 
intracellular levels of Rac1-GTP with an IC50 value equal to 5.8 
µM, while the (+)AR-148  was inactive. Accordingly, the 
racemate AR-148 inhibited the Rac1 activity with an IC50 of 
21.7µM. These data clearly demonstrated an enantioselective 
effect of (-)AR-148 on Rac1. (Figure 4, Experimental SI) 
 
 
Fig. 4. Dose-dependent effect of AR148 and its enantiomers on Rac1-GTP 
levels. SMCs were seeded at a density of 2×105/35 mm Petri dish and 
incubated with DMEM supplemented with 10% FCS; 24 h later the medium 
was changed to one containing 0.4% FCS, and the cultures were incubated 
for 48 h. At this time, the compounds were added to the cultured medium 
at a final concentration of 1, 2.5, 5 and 10 μM, and after 4 h Rac activation 
was induced by PDGF-BB (20 ng/mL) for 2 min. Total protein extracts and G-
LISA assays were then performed. 
Conclusions 
In summary we reported a gram scale, protecting group-free 
synthesis of compound AR-148, a known potent inhibitor of 
Rac1-Tiam1 protein protein interaction. The synthetic strategy 
applied, includes the first example of phosphine free Heck 
hydroarylation reaction on an olefin which represents an 
improvement also in term of eco-friendly and atom economy of 
the process. We were able to exploit the remote directing group 
effect of the free amine for the selective obtainment of the 
desired regioisomer of the arylation reaction.. Despite the 
impossibility of an enantiopure synthesis, we separated and 
purified the two enantiomers of AR-148 and we demonstrated 
for the first time the enantioselectivity in the inhibition of Rac1-
Tiam1 PPI by (-)-AR-148. Characterization of the absolute 
stereochemistry of (-)AR-148 and study of cocrystalization with 
the Rac1 protein are proceeding in order to define the 
pharmacophoric model for a further drug design. 
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